LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 8 of total 8

Search options

  1. Article ; Online: Rapid radiological improvement of COVID-19 pneumonia after treatment with tocilizumab.

    Comel, Andrea Claudio / Mosaner, Walter / Bragantini, Damiano / Lanzafame, Massimiliano

    Infection

    2020  Volume 49, Issue 1, Page(s) 195–196

    MeSH term(s) Antibodies, Monoclonal, Humanized/administration & dosage ; Antibodies, Monoclonal, Humanized/adverse effects ; Antibodies, Monoclonal, Humanized/therapeutic use ; Biomarkers ; COVID-19/diagnosis ; COVID-19/drug therapy ; COVID-19/metabolism ; COVID-19/virology ; Combined Modality Therapy ; Humans ; Male ; Middle Aged ; Radiography, Thoracic ; Receptors, Interleukin-6/antagonists & inhibitors ; SARS-CoV-2/drug effects ; Symptom Assessment ; Tomography, X-Ray Computed ; Treatment Outcome
    Chemical Substances Antibodies, Monoclonal, Humanized ; Biomarkers ; IL6R protein, human ; Receptors, Interleukin-6 ; tocilizumab (I031V2H011)
    Keywords covid19
    Language English
    Publishing date 2020-06-15
    Publishing country Germany
    Document type Case Reports ; Journal Article
    ZDB-ID 185104-4
    ISSN 1439-0973 ; 0300-8126 ; 0173-2129
    ISSN (online) 1439-0973
    ISSN 0300-8126 ; 0173-2129
    DOI 10.1007/s15010-020-01449-w
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 881: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 528: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article: Rapid radiological improvement of COVID-19 pneumonia after treatment with tocilizumab

    Comel, Andrea Claudio / Mosaner, Walter / Bragantini, Damiano / Lanzafame, Massimiliano

    Infection

    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #601110
    Database COVID19

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  3. Article ; Online: Rapid radiological improvement of COVID-19 pneumonia after treatment with tocilizumab

    Comel, Andrea Claudio / Mosaner, Walter / Bragantini, Damiano / Lanzafame, Massimiliano

    Infection ; ISSN 0300-8126 1439-0973

    2020  

    Keywords Microbiology (medical) ; Infectious Diseases ; General Medicine ; covid19
    Language English
    Publisher Springer Science and Business Media LLC
    Publishing country us
    Document type Article ; Online
    DOI 10.1007/s15010-020-01449-w
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  4. Article ; Online: Observational, multicentre study on the epidemiology of haemoptysis.

    Mondoni, Michele / Carlucci, Paolo / Job, Sara / Parazzini, Elena Maria / Cipolla, Giuseppe / Pagani, Matteo / Tursi, Francesco / Negri, Luigi / Fois, Alessandro / Canu, Sara / Arcadu, Antonella / Pirina, Pietro / Bonifazi, Martina / Gasparini, Stefano / Marani, Silvia / Comel, Andrea Claudio / Ravenna, Franco / Dore, Simone / Alfano, Fausta /
    Sferrazza Papa, Giuseppe Francesco / Di Marco, Fabiano / Centanni, Stefano / Sotgiu, Giovanni

    The European respiratory journal

    2018  Volume 51, Issue 1

    MeSH term(s) Acute Disease ; Aged ; Bronchi/pathology ; Bronchitis/complications ; Bronchoscopy ; Embolization, Therapeutic/methods ; Female ; Hemoptysis/epidemiology ; Hemoptysis/etiology ; Hemorrhage ; Humans ; Interdisciplinary Communication ; Italy ; Lung Neoplasms/complications ; Male ; Middle Aged ; Pneumonia/complications ; Prospective Studies ; Retrospective Studies ; Tomography, X-Ray Computed
    Language English
    Publishing date 2018-01-04
    Publishing country England
    Document type Clinical Trial ; Letter ; Multicenter Study ; Observational Study
    ZDB-ID 639359-7
    ISSN 1399-3003 ; 0903-1936
    ISSN (online) 1399-3003
    ISSN 0903-1936
    DOI 10.1183/13993003.01813-2017
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2322: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 292: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Baricitinib restrains the immune dysregulation in patients with severe COVID-19.

    Bronte, Vincenzo / Ugel, Stefano / Tinazzi, Elisa / Vella, Antonio / De Sanctis, Francesco / Canè, Stefania / Batani, Veronica / Trovato, Rosalinda / Fiore, Alessandra / Petrova, Varvara / Hofer, Francesca / Barouni, Roza Maria / Musiu, Chiara / Caligola, Simone / Pinton, Laura / Torroni, Lorena / Polati, Enrico / Donadello, Katia / Friso, Simonetta /
    Pizzolo, Francesca / Iezzi, Manuela / Facciotti, Federica / Pelicci, Pier Giuseppe / Righetti, Daniela / Bazzoni, Paolo / Rampudda, Mariaelisa / Comel, Andrea / Mosaner, Walter / Lunardi, Claudio / Olivieri, Oliviero

    The Journal of clinical investigation

    2020  Volume 130, Issue 12, Page(s) 6409–6416

    Abstract: BACKGROUNDPatients with coronavirus disease 2019 (COVID-19) develop pneumonia generally associated with lymphopenia and a severe inflammatory response due to uncontrolled cytokine release. These mediators are transcriptionally regulated by the JAK/STAT ... ...

    Abstract BACKGROUNDPatients with coronavirus disease 2019 (COVID-19) develop pneumonia generally associated with lymphopenia and a severe inflammatory response due to uncontrolled cytokine release. These mediators are transcriptionally regulated by the JAK/STAT signaling pathways, which can be disabled by small molecules.METHODSWe treated a group of patients (n = 20) with baricitinib according to an off-label use of the drug. The study was designed as an observational, longitudinal trial and approved by the local ethics committee. The patients were treated with 4 mg baricitinib twice daily for 2 days, followed by 4 mg per day for the remaining 7 days. Changes in the immune phenotype and expression of phosphorylated STAT3 (p-STAT3) in blood cells were evaluated and correlated with serum-derived cytokine levels and antibodies against severe acute respiratory syndrome-coronavirus 2 (anti-SARS-CoV-2). In a single treated patient, we also evaluated the alteration of myeloid cell functional activity.RESULTSWe provide evidence that patients treated with baricitinib had a marked reduction in serum levels of IL-6, IL-1β, and TNF-α, a rapid recovery of circulating T and B cell frequencies, and increased antibody production against the SARS-CoV-2 spike protein, all of which were clinically associated with a reduction in the need for oxygen therapy and a progressive increase in the P/F (PaO2, oxygen partial pressure/FiO2, fraction of inspired oxygen) ratio.CONCLUSIONThese data suggest that baricitinib prevented the progression to a severe, extreme form of the viral disease by modulating the patients' immune landscape and that these changes were associated with a safer, more favorable clinical outcome for patients with COVID-19 pneumonia.TRIAL REGISTRATIONClinicalTrials.gov NCT04438629.FUNDINGThis work was supported by the Fondazione Cariverona (ENACT Project) and the Fondazione TIM.
    MeSH term(s) Aged ; Aged, 80 and over ; Azetidines/administration & dosage ; B-Lymphocytes/immunology ; B-Lymphocytes/metabolism ; B-Lymphocytes/pathology ; COVID-19/blood ; COVID-19/drug therapy ; COVID-19/immunology ; COVID-19/pathology ; Cytokines/blood ; Cytokines/immunology ; Female ; Humans ; Longitudinal Studies ; Male ; Middle Aged ; Off-Label Use ; Purines/administration & dosage ; Pyrazoles/administration & dosage ; SARS-CoV-2/immunology ; SARS-CoV-2/metabolism ; Severity of Illness Index ; Sulfonamides/administration & dosage ; T-Lymphocytes/immunology ; T-Lymphocytes/metabolism ; T-Lymphocytes/pathology
    Chemical Substances Azetidines ; Cytokines ; Purines ; Pyrazoles ; Sulfonamides ; baricitinib (ISP4442I3Y)
    Keywords covid19
    Language English
    Publishing date 2020-08-14
    Publishing country United States
    Document type Clinical Trial ; Journal Article ; Multicenter Study ; Observational Study
    ZDB-ID 3067-3
    ISSN 1558-8238 ; 0021-9738
    ISSN (online) 1558-8238
    ISSN 0021-9738
    DOI 10.1172/JCI141772
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ua VI Zs.184: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Baricitinib restrains the immune dysregulation in severe COVID-19 patients

    Bronte, Vincenzo / Ugel, Stefano / Tinazzi, Elisa / Vella, Antonio / De Sanctis, Francesco / Canè, Stefania / Batani, Veronica / Trovato, Rosalinda / Fiore, Alessandra / Petrova, Varvara / Hofer, Francesca / Barouni, Roza Maria / Musiu, Chiara / Caligola, Simone / Pinton, Laura / Torroni, Lorena / Polati, Enrico / Donadello, Katia / Friso, Simonetta /
    Pizzolo, Francesca / Iezzi, Manuela / Facciotti, Federica / Pelicci, Pier Giuseppe / Righetti, Daniela / Bazzoni, Paolo / Rampudda, Mariaelisa / Comel, Andrea C / Mosaner, Walter / Lunardi, Claudio / Olivieri, Oliviero

    2020  

    Abstract: COVID-19 patients develop pneumonia generally associated to lymphopenia and severe inflammatory response due to uncontrolled cytokine release. These mediators are transcriptionally regulated by the JAK-STAT signaling pathways, which can be disabled by ... ...

    Abstract COVID-19 patients develop pneumonia generally associated to lymphopenia and severe inflammatory response due to uncontrolled cytokine release. These mediators are transcriptionally regulated by the JAK-STAT signaling pathways, which can be disabled by small molecules.
    Keywords COVID-19 ; Immunology ; Innate immunity ; covid19
    Language English
    Publishing country it
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  7. Article: Baricitinib restrains the immune dysregulation in patients with severe COVID-19

    Bronte, Vincenzo / Ugel, Stefano / Tinazzi, Elisa / Vella, Antonio / De Sanctis, Francesco / Canè, Stefania / Batani, Veronica / Trovato, Rosalinda / Fiore, Alessandra / Petrova, Varvara / Hofer, Francesca / Barouni, Roza Maria / Musiu, Chiara / Caligola, Simone / Pinton, Laura / Torroni, Lorena / Polati, Enrico / Donadello, Katia / Friso, Simonetta /
    Pizzolo, Francesca / Iezzi, Manuela / Facciotti, Federica / Pelicci, Pier Giuseppe / Righetti, Daniela / Bazzoni, Paolo / Rampudda, Mariaelisa / Comel, Andrea / Mosaner, Walter / Lunardi, Claudio / Olivieri, Oliviero

    J. clin. invest

    Abstract: BACKGROUNDPatients with coronavirus disease 2019 (COVID-19) develop pneumonia generally associated with lymphopenia and a severe inflammatory response due to uncontrolled cytokine release. These mediators are transcriptionally regulated by the JAK/STAT ... ...

    Abstract BACKGROUNDPatients with coronavirus disease 2019 (COVID-19) develop pneumonia generally associated with lymphopenia and a severe inflammatory response due to uncontrolled cytokine release. These mediators are transcriptionally regulated by the JAK/STAT signaling pathways, which can be disabled by small molecules.METHODSWe treated a group of patients (n = 20) with baricitinib according to an off-label use of the drug. The study was designed as an observational, longitudinal trial and approved by the local ethics committee. The patients were treated with 4 mg baricitinib twice daily for 2 days, followed by 4 mg per day for the remaining 7 days. Changes in the immune phenotype and expression of phosphorylated STAT3 (p-STAT3) in blood cells were evaluated and correlated with serum-derived cytokine levels and antibodies against severe acute respiratory syndrome-coronavirus 2 (anti-SARS-CoV-2). In a single treated patient, we also evaluated the alteration of myeloid cell functional activity.RESULTSWe provide evidence that patients treated with baricitinib had a marked reduction in serum levels of IL-6, IL-1ß, and TNF-α, a rapid recovery of circulating T and B cell frequencies, and increased antibody production against the SARS-CoV-2 spike protein, all of which were clinically associated with a reduction in the need for oxygen therapy and a progressive increase in the P/F (PaO2, oxygen partial pressure/FiO2, fraction of inspired oxygen) ratio.CONCLUSIONThese data suggest that baricitinib prevented the progression to a severe, extreme form of the viral disease by modulating the patients' immune landscape and that these changes were associated with a safer, more favorable clinical outcome for patients with COVID-19 pneumonia.TRIAL REGISTRATIONClinicalTrials.gov NCT04438629.FUNDINGThis work was supported by the Fondazione Cariverona (ENACT Project) and the Fondazione TIM.
    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #721245
    Database COVID19

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  8. Article ; Online: Perioperative management of antiplatelet therapy in patients with coronary stents undergoing cardiac and non-cardiac surgery: a consensus document from Italian cardiological, surgical and anaesthesiological societies.

    Rossini, Roberta / Musumeci, Giuseppe / Visconti, Luigi Oltrona / Bramucci, Ezio / Castiglioni, Battistina / De Servi, Stefano / Lettieri, Corrado / Lettino, Maddalena / Piccaluga, Emanuela / Savonitto, Stefano / Trabattoni, Daniela / Capodanno, Davide / Buffoli, Francesca / Parolari, Alessandro / Dionigi, Gianlorenzo / Boni, Luigi / Biglioli, Federico / Valdatta, Luigi / Droghetti, Andrea /
    Bozzani, Antonio / Setacci, Carlo / Ravelli, Paolo / Crescini, Claudio / Staurenghi, Giovanni / Scarone, Pietro / Francetti, Luca / D'Angelo, Fabio / Gadda, Franco / Comel, Andrea / Salvi, Luca / Lorini, Luca / Antonelli, Massimo / Bovenzi, Francesco / Cremonesi, Alberto / Angiolillo, Dominick J / Guagliumi, Giulio

    EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology

    2014  Volume 10, Issue 1, Page(s) 38–46

    Abstract: Optimal perioperative antiplatelet therapy in patients with coronary stents undergoing surgery still remains poorly defined and a matter of debate among cardiologists, surgeons and anaesthesiologists. Surgery represents one of the most common reasons for ...

    Abstract Optimal perioperative antiplatelet therapy in patients with coronary stents undergoing surgery still remains poorly defined and a matter of debate among cardiologists, surgeons and anaesthesiologists. Surgery represents one of the most common reasons for premature antiplatelet therapy discontinuation, which is associated with a significant increase in mortality and major adverse cardiac events, in particular stent thrombosis. Clinical practice guidelines provide little support with regard to managing antiplatelet therapy in the perioperative phase in the case of patients with non-deferrable surgical interventions and/or high haemorrhagic risk. Moreover, a standard definition of ischaemic and haemorrhagic risk has never been determined. Finally, recommendations shared by cardiologists, surgeons and anaesthesiologists are lacking. The present consensus document provides practical recommendations on the perioperative management of antiplatelet therapy in patients with coronary stents undergoing surgery. Cardiologists, surgeons and anaesthesiologists have contributed equally to its creation. On the basis of clinical and angiographic data, the individual thrombotic risk has been defined. All surgical interventions have been classified according to their inherent haemorrhagic risk. A consensus on the optimal antiplatelet regimen in the perioperative phase has been reached on the basis of the ischaemic and haemorrhagic risk. Aspirin should be continued perioperatively in the majority of surgical operations, whereas dual antiplatelet therapy should not be withdrawn for surgery in the case of low bleeding risk. In selected patients at high risk for both bleeding and ischaemic events, when oral antiplatelet therapy withdrawal is required, perioperative treatment with short-acting intravenous glycoprotein IIb/IIIa inhibitors (tirofiban or eptifibatide) should be taken into consideration.
    MeSH term(s) Anesthesiology ; Aspirin/therapeutic use ; Cardiac Surgical Procedures/methods ; Cardiology ; Hemorrhage/prevention & control ; Humans ; Italy ; Myocardial Ischemia/prevention & control ; Peptides/therapeutic use ; Perioperative Care/standards ; Platelet Aggregation Inhibitors/therapeutic use ; Platelet Glycoprotein GPIIb-IIIa Complex/antagonists & inhibitors ; Risk Assessment ; Societies, Medical ; Stents ; Surgical Procedures, Operative/methods ; Thoracic Surgery ; Ticlopidine/analogs & derivatives ; Ticlopidine/therapeutic use ; Tyrosine/analogs & derivatives ; Tyrosine/therapeutic use
    Chemical Substances Peptides ; Platelet Aggregation Inhibitors ; Platelet Glycoprotein GPIIb-IIIa Complex ; Tyrosine (42HK56048U) ; clopidogrel (A74586SNO7) ; tirofiban (GGX234SI5H) ; eptifibatide (NA8320J834) ; Ticlopidine (OM90ZUW7M1) ; Aspirin (R16CO5Y76E)
    Language English
    Publishing date 2014-05
    Publishing country France
    Document type Consensus Development Conference ; Journal Article ; Practice Guideline
    ZDB-ID 2457174-X
    ISSN 1969-6213 ; 1774-024X
    ISSN (online) 1969-6213
    ISSN 1774-024X
    DOI 10.4244/EIJV10I1A8
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6680: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 571: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top